IMUGENE LIMITED — AGM Information 2012

Nov 29, 2012

Imugene Annual General Meeting Presentation by Executive Chairman

==> picture [198 x 65] intentionally omitted <==

Dear Shareholders,

Thank you for joining us today at Imugene’s Annual General Meeting for the 2011/2012 financial year.

No doubt you are aware that this company has undergone significant change in the past year. Following a thorough review the decision was taken to cease development of the company’s animal health assets and shift our focus to concentrate solely on advancing our drug delivery technology, Linguet, which was acquired in August.

I firmly believe this new direction for the company is a path that will generate shareholder returns. The Linguet platform technology is a powerful tool with a very simple value proposition – it makes good drugs even better. Importantly, we have a well-defined strategy in place to extract value from this technology and we are very focused on opportunities that will enable the company to begin generating revenues by Financial Year 2014. Driving this is a team that is highly experienced in monetising life science assets, and with a depth of knowledge in the drug candidates that we are bringing to market initially.

Before we commence the formal business and then on to Dr Nick Ede to take you through a presentation of the science, I would like to spend a few moments introducing the Board and Management team. We have assembled a very high calibre team, with the ability to take this technology forward – and who will prove to be a great asset to this company.

• Paul Hopper

• Steve Harris

• Steve Martin

• Dr Nick Ede

Since the new Board and management team has come on board we have focused our efforts on developing the strategy for Linguet, and completing the review of the vaccine and animal health assets.

Chairman Address

30 November 2012

Imugene Limited

We have a sound commercial strategy, a highly experienced and capable team and a promising technology. In short, we have amassed the ingredients for creating a company with excellent commercial potential. So now it is time to get the job done.

I know that many of you have been asking for updates. We will keep you regularly updated via our ASX announcements and other shareholder communication as we progress.

In summary, I believe we have an exciting year ahead of us and I look forward to sharing this journey with you.

Thank you.

Chairman Address

30 November 2012

Imugene Limited

==> picture [312 x 65] intentionally omitted <==

==> picture [255 x 251] intentionally omitted <==

AGM 30[th] November 2012 www.imugene.com

A new direction for Imugene�

==> picture [780 x 84] intentionally omitted <==

• In July 2012, IMU acquired Lingual Consegna Pty Ltd and it’s Intellectual Property of Linguet™;�

• Linguet™ is an oral buccal drug delivery technology that will be developed and commercialised with the support of the Linguet scientific team including Dr Nicholas Ede PhD and Steve Martin;�

• Pig and poultry vaccine platform terminated due to lack of commercial interest; and�

• IMU Board appointments of Fabio Pannuti, Steve Harris and Paul Hopper.�

==> picture [98 x 21] intentionally omitted <==

Board and Management�

• Board of Directors (L to R below) Fabio Pannuti, Steve Harris and Paul Hopper�

==> picture [197 x 201] intentionally omitted <==

==> picture [201 x 202] intentionally omitted <==

==> picture [149 x 202] intentionally omitted <==

• Head of Development: Mr Steve Martin, Dr Nicholas Ede�

• Please visit www.imugene.com for biography’s and further details�

==> picture [98 x 21] intentionally omitted <==

Linguet™: the opportunity�

==> picture [298 x 202] intentionally omitted <==

Up to 50% of the general population suffers from difficulty in swallowing tablets.[ 2�] Oral medicine is the largest segment of pharmaceuticals yet there are few solutions for the dysphagia (swallowing problems) market

• Linguet can enhance the performance of drugs that are poorly absorbed or tolerated �

• Potentially allows lower doses of the active drug with better results�

• Improves patient compliance�

• Particularly important in context of lowering healthcare costs associated with ageing population�

• Extends the patent life of existing drugs�

==> picture [98 x 21] intentionally omitted <==

1. Sastry et al Pharm Sci & Tech Today 3: 138-145, 2000 2. Seager J Pharma Pharmacol 50: 375-382, 1998

Linguet™: a platform technology with clear commercial opportunities �

• Linguet is targeted at those drugs that:�

• Show poor oral bioavailability (e.g. progesterone, testosterone);�

• Require rapid onset of action (e.g. analgesics, erectile dysfunction products);�

• Cause gastro-intestinal irritation (e.g. NSAIDs, bisphosphonates & statins);�

• Are degraded in the gastro-intestinal tract (GIT) and require dose compensation (e.g. hormone replacement formulations); and�

==> picture [206 x 127] intentionally omitted <==

• Are adversely affected by high first-pass metabolism in the liver and thus rely on massive over dosing in order to deliver the correct therapeutic outcome (e.g. pain relief).�

==> picture [98 x 21] intentionally omitted <==

Linguet™: a targeted technology with wide applications�

Linguet™ is able to be used in a wide range of therapeutic applications enabling a rich hunting ground to create world-class products that meet the commercial need. � Such breadth of choice allows for a de-risked business model.

==> picture [723 x 138] intentionally omitted <==

==> picture [732 x 167] intentionally omitted <==

----- Start of picture text -----

CNS Vaginal
Psychiatric conditions- Infections
conditions -
Parkinson’s Pain including Anti-
Pectoris�Angina Insomnia� Nausea� disorder, Bipolar Disease, palliative inflammatory Dysfunction�Sexual (Candiasis and Vaginitis�
Epilepsy, care, migraine� disease�
Anxiety, Alzheimer’s Bacterial
Schizophrenia� Disease� Vaginosis)�
----- End of picture text -----

Linguet™: a clear pathway to commercialisation

Linguet has a clear commercialisation strategy to deliver short term revenues & significant long term growth:�

Use of a nutrition (analogue of Vitamin D) product to validate manufacturing and production of Linguet Specific research system to cGMP based upon standards. Resultant optimisation of IP product can be sold portfolio. Target the or licensed� use for NSAIDS and Commencement of Erectile Dysfunction� own product development plan�

Development of Linguet™ PLUS including manufacturing and proof of concept�

==> picture [98 x 21] intentionally omitted <==

Linguet : Commercialisation Strategy�

• The Linguet product development program should focus upon simple selection criteria as below�

==> picture [67 x 269] intentionally omitted <==

Low
Cost Low
Risk Low
IP Short
Bme
to
commercialisaBon

High
Cost High
Risk High
IP Long
Bme
to
commercialisaBon

A:
Fast
to
market
products,
technically
simple, low
hanging
fruit.
Large
range,
limited
value. EU
focused.

B:
Require
more
clinical
data
with longer
Bmelines
and
higher
cost
than
A molecules.
Less
opportuniBes.
Transfer of
A
molecules
to
US
–
increased
IP required

C:
US
focused,
high
value
high
risk developments.
High
Reward, requires
strong
IP
family.
Limited opportuniBes

==> picture [98 x 21] intentionally omitted <==

Linguet™: development plan – key milestones�

==> picture [780 x 280] intentionally omitted <==

----- Start of picture text -----

Parallel
First
Nutri)onal
First
In-­‐vivo
First
Pharma
First
EU
Filing
Development
Supplement
study
Commercial
Commences
available
for
Agreements
partnering
Q2-­‐3
Q4
2012
Q1
2013
Q4
2013
Q1
2014
Q1-­‐2
2014
2013
----- End of picture text -----

==> picture [98 x 21] intentionally omitted <==